chrisvoncsefalvay/vaers-outcomes huggingface dataset:
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 28Mar2021 as dose 1, single (Batch/Lot number: unknown), in left arm and on 18Apr2021 as dose 2, single (Batch/Lot number: unknown) at the age of 54 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), on 22Oct2021 at 20:00 as dose 3 (booster), single (Batch/Lot number: unknown), in right arm for covid-19 immunisation. The patient's relevant medical history included: "Diabetes T1" (unspecified if ongoing); "allergies" (unspecified if ongoing); "Heart" (unspecified if ongoing); "Back" (unspecified if ongoing). Concomitant medication(s) included: INSULIN. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19. Clinical course: No known allergies. The patient received other medications in 2 weeks are Insulin, many, medications for chronic illness. The patient was treated for COVID 19 with Paxlovid from 16May2022 to 22May2022.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
broke out in rash & hives (entire body), body temp, eyes & ears swell-ears felt like full of hot wax-very warm
Patient reports intense pain a few hours following injection. Patient reports pain that radiated all the way into her neck.
Initial report received from nurse on 02 Dec 2009: The reporter stated that this child who was younger than 4 years was given FLUVIRIN H1N1 on 02 Dec 2009. No adverse event was reported.
Shaking uncontrollably, cold, muscular and joint pain, flu-like symptoms.
Vaccines administered 8-15-13. Initial discomfort which resolved. On 8-19 noted redness, pain and swelling at site. Diagnosed with cellulitis on 8-21-12 (L arm) and treated with clinda.
Rash on arm where site was; This is a spontaneous report received from a contactable consumer (Patient's sister). A female patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot: unknown), via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunization. Patient's medical history included cancer. The patient's concomitant medications were not reported. Caller stated her sister who has cancer received the same Pfizer vaccine and did not have any reactions but then stated her sister had a rash on her arm at the vaccination site but it went away. There was no investigation assessment. The report is cross referenced to report ID: QGAEOUVI. Caller did not have any further details for report. It was report 2 of 7. The outcome of the event was recovered.  No follow-up attempts are needed. Information about lot/batch number cannot be obtained.
Narrative: Pt presented to ED on 8/21/2022 at 2245 with c/o productive cough x 3-4 days and SOB, occurring over past day. Pt reports COVID exposure through family friend. Pt admitted with primary diagnosis of: Acute COVID 19 infection Acute on chronic hypoxic respiratory failure AKI on stage IIIb CKD RUE hematoma - resolving Pt hospitalized 8/22/22 - 8/26/22. ADDITIONAL DIAGNOSES: Type II DM HTN HLD Chronic hypoxic respiratory failure on 4 liters 02 due COPD Chronic CHF due diastolic dysfunction Stage IIIb CKD ETOH dependence Leukocytoclastic vasculitis Macrocytic anemia/pancytopenia Chronic Constipation: h/o Tubular Adenoma HOSPITAL COURSE: Patient is a 79 yo gentleman with Stage IIIb CKD, Chronic CHF due to diastolic dysfunction,chronic hypoxic respiratory failure due to COPD, Type II DM, parosymal afib/aflutter, alcohol dependence who was admitted on 8/21/22 with acute COVID 19 pneumonia. He was admitted to the medical floor on airborne precautions and started on decadron and remdesivir. There was concern for PE given hypoxia, COVID and indeterminate V/Q (unable to obtain CTA due to AKI on admission). However the patient could not anticoagulation due to RUE hematoma at blood pressure cuff site. BLE US were negative for DVT. Hypoxia resolved.
The arms and legs are magneted. Metal articles stick to the body as if you had magnets and the extremities fall asleep a lot.
I have developed a rash in my arm and it seems to be sticking around; pink; The site started itching; rash; This spontaneous case was reported by a consumer and describes the occurrence of STICKY SKIN (I have developed a rash in my arm and it seems to be sticking around), PHOTOSENSITIVITY REACTION (pink), PRURITUS (The site started itching) and RASH (rash) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Feb-2021, the patient experienced STICKY SKIN (I have developed a rash in my arm and it seems to be sticking around), PHOTOSENSITIVITY REACTION (pink), PRURITUS (The site started itching) and RASH (rash). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, STICKY SKIN (I have developed a rash in my arm and it seems to be sticking around), PHOTOSENSITIVITY REACTION (pink), PRURITUS (The site started itching) and RASH (rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided.   Most recent FOLLOW-UP information incorporated above includes: On 09-Feb-2021: No specific follow-up information recorded.
Patient has rash on whole body that presented at  about 8 pm 7/7/21
Information has been received from a physician concerning a child who on an unspecified date was vaccinated with the third dose of ROTATEQ (Lot # and date of administration were not reported). It was reported that the patient became infected with rotavirus after receiving all three doses of ROTATEQ. It was reported that the patient was examined in the emergency room and then sent home. It was reported that the patient received intravenous fluids. It was reported that the patient had recovered at the time of the report. The reporting physician considered that the patient received intravenous fluids to be other important medical event. This is one of several cases from the same source. No further information is available.
This is a spontaneous report from a Pfizer-sponsored program COVAX US Support. A contactable consumer or other non HCP (Patient) reported that a male patient of an unspecified age received bnt162b2 (BNT162B2, Formulation; Solution for injection), dose 1 via an unspecified route of administration on 17Feb2021 (Batch/Lot number was not reported) as DOSE 1, SINGLE for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. The patient reports worsening arthritis after first dose on 17Feb2021. The outcome of event reported as unknown. The lot/batch number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information is expected.
pt recvd flu vax & exp itching 3 hrs later; pruritus affected face, head, back, shoulders, & arms; given DPH;
Developed fever, fatigue, extreme joint pain, HA, ear ache, tachycardia, SOB.  Had Covid 11/4, and these are all symptoms that she had when she had Covid.  Continues with HA, ear ache, joint pain, fatigue and SOB today.  MD has not responded yet.
Student had first signs of breaking out on 09/19/05.  No fever.  OTC itch cream used at home.  Out of school 09/19/05-09/23/05
Patient told me that she began to have a headache on Sunday (4/27) after taking her first dose. She said that today she has hives and feels hot.
Patient is a very pleasant 92-year-old male who presented from his independent living facility to the local HCF on 1/1/2023 with significant global and lower extremity weakness in the setting of recently diagnosed COVID-19 (already on Paxlovid)..  His lab and imaging work-up were unremarkable and he remained on room air without signs of cardiopulmonary distress.  He improved quite rapidly in the hospital and was nearly back to his baseline within 24 hours.  He was not a candidate for advanced COVID therapeutics.  He was assessed by PT/OT and will be a candidate for home health care services, which will need to be arranged after discharged.  Patient and wife requested discharged home on 1/2/2023.  He will have close follow-up with his PCP.  COVID supportive care resources were placed on his after visit summary
After the MMR vaccine my son developed a quarter sized lump on his neck.  The same Doctor's office diagnosed it as "clumped lymph nodes."
Patient presented with mild symptoms of Erythema Multiforme distributing from vaccination site 14 days post vaccination.  Patient required no treatment and spontaneously resolved within 3 days.
10m 3 wk old had  INTUSSUSCEPTION, had previously had 3 doses of Rotateq at correct schedule, last dose on 10/20/08 10/20/08-office visit-well baby exam. C/O constipation.  4/2/09-records received for DOS 3/9-3/9/09-DC DX:Febrile illness began on 3/6/09, seen in office normal physical exam, thought to have a viral infection. Fever broke and appeared fine. On day of admission woke up very irritable and acting like her stomach hurt, started vomiting, nonbilious. Seen in ED thought to have gastroenteritis. Returned later that afternoon after patient had a stool with bright red color and a second stool deeper red. Stool positive heme.
Long Term Care resident received a 4th dose inadvertently, no adverse reaction noted. Family and MD made aware.
(L) deltoid arm, skin redness, swelling which began worsening 1d after vaccination today measured as 6.5 cm erythema (+) tenderness.
sl t100-101 during day of inject; 4MAR92 t104 2AM crying unconsolably; pt taken to ER; admitted to hosp for OM x 2 days;
Barely feel 2 of my fingers; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Barely feel 2 of my fingers) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPOAESTHESIA (Barely feel 2 of my fingers). At the time of the report, HYPOAESTHESIA (Barely feel 2 of my fingers) had not resolved.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   No concomitant medication listed.   No treatment information provided.
The following morning was more the achy feeling, headache and the arm was sore and the rash that traveled down the arm and this lasted 2 days, the third day it was my arm only feeling very uncomfortable.
This spontaneous report as received from a health care worker refers to an unspecified number of patients of unknown age and gender. No information regarding the patients' concurrent conditions, pertinent medical history, concomitant medications, drug reactions, or allergies was provided. On unknown dates, the patients were vaccinated with improperly stored doses of VARIVAX, injection (lot # L032395, expiration date: 26-AUG-2017; lot# L042267, expiration date: 27-OCT-2017; lot# M002062, expiration date 21-JAN-2018; dose and route of administration were not provided). No adverse events were reported. Administered doses of vaccine experienced the following temperature excursion: 9.9 F for 15 mins 7.3 F for 15 mins 9.0 F for 15 mins 7.9 F for 15 mins 9.9 F for 15 mins 11.7 F for 15 mins 10.2 F for 15 mins 6.8 F for 15 mins 7.3 F for 15 mins 10.9 F for 15 mins 14.9 F for 15 mins 6.1 F for 15 mins 5.9 F for 15 mins 6.4 F for 15 mins 6.3 F for 15 mins 6.3 F for 15 mins 12.6 F for 15 mins 7.3 F for 15 mins 6.3 F for 15 mins 6.6 F for 15 mins 6.3 F for 15 mins 6.3 F for 15 mins 13.6 F for 15 mins 7.7 F for 15 mins 6.4 F for 15 mins 6.6 F for 15 mins 7.3 F for 15 mins 6.3 F for 15 mins 6.6 F for 15 mins 6.3 F for 15 mins 6.6 F for 15 mins 6.3 F for 15 mins 6.6 F for 15 mins 6.4 F for 15 mins 6.8 F for 15 mins There were no previous temperature excursions. Digital data logger was involved. Additional information has been requested.
Went to hospital on 19th. Reported bilateral lower ext. weakness. Diagnosed at hospital with Guillain-Barre like syndrome.
(The 3rd shot was on 11/21/21 which there was nowhere to put above) After shots 2 and 3 My husband was ok for some hours. Then in the evening/late in the night he started behaving and talking strangely. The first time I heard him out in the dark hallway shouting, ?Woweeee! It?s really dark out here!! Whoopeeee!? I got him back to bed but he didn?t sleep. He was just saying crazy things and laughing. I asked him if he was going ?round the bend and he just stared at me. If I asked him anything, he simply couldn?t comprehend it. (This is a man with a Ph.D.)  The same thing happened after the booster shot minus the adventure in the hallway. I thought since it was a half dose, nothing would happen. But it was just as bad. The first time the next morning I called 911. He was taken by ambulance to Hospital of the emergency department. He was dehydrated and was hooked up to take care of that. He was given other tests but nothing was wrong. The second time I kept him at home because I ended up having to pay for the ambulance. Within in one day he was himself in both cases.
Pt reported at PCP visit 11/9 that after the 2nd Pfizer dose, she developed hives that come and go.  Pt still notes occasional hives.  Pt does not take anything for the hives but tries not to scratch
Real red; swollen; Burning; soreness; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Real red), VACCINATION SITE SWELLING (swollen), VACCINATION SITE PAIN (Burning) and VACCINATION SITE PAIN (soreness) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024M207) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ERYTHEMA (Real red), VACCINATION SITE SWELLING (swollen), VACCINATION SITE PAIN (Burning) and VACCINATION SITE PAIN (soreness). At the time of the report, ERYTHEMA (Real red), VACCINATION SITE SWELLING (swollen), VACCINATION SITE PAIN (Burning) and VACCINATION SITE PAIN (soreness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   Patient reported it took three days for soreness to start and she put some alcohol on her arm to treat symptoms.
2 months later, headache, body aches, dizziness, sinus blockage and significant loss of hearing in one ear. Facial numbness on one side.
24 hours after shot: muscle aches, fatigue, joint pain, swollen lymph nodes in armpit on side of injection, nausea, fever up to 103.1 (mostly stayed between 102.5 and 102.9 for 24 hours)   36 hours after: bad headache and very bad neck pain/stiff neck, swollen lymph nodes along jaw, continued aches and nausea; fever resolved after 36 hours
diagnosed as having AFIB.; light headed; I had some aches; I was completely down in bed with no energy/physically weak; This is a spontaneous report from a contactable consumer (patient). A 79-year-old male patient received the second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number: EN6202), via an unspecified route of administration administered in left arm on 23Feb2021 00:15 as SINGLE DOSE for COVID-19 immunisation. The patient had no COVID prior vaccination and was not tested for COVID post vaccination. Medical history included hypertension. The patient had no known allergies. Concomitant medications included atenolol, oxybutynin, and tamsulosin. Historical vaccine includes first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE) on an unspecified date (at the age of 79-year-old) for COVID-19 immunisation. The patient stated that in the past her pulse rate was in the low 60's. The patient lost energy gradually from 23Feb2021 until 26Feb2021 and 27Feb2021. The patient was completely down in bed with no energy. The patient had some aches on 25Feb2021 at 07:00 AM, but the pulse rate went up to 80 to 100. The patient went to the Cardiologist he believes on 08Mar2021 and was diagnosed as having atrial fibrillation (AFIB) on 08Mar2021. The patient was being treated for AFIB now and have been light headed and physically weak since 25Feb2021 at 07:00 AM. Therapeutic measures were taken as a result of diagnosed as having afib. The patient had not yet recovered from the events.
3/27/07 Shoulder to elbow - red, hot, hard 101.2 fever swollen lymph node under arm tx'ed with prednisone/antihistamine
Developed localized pain, tenderness, subsequent redness and swelling at the site of injection. Mild erythema and warmth with soft tissue swelling. No erythematous streaks.
extremely sore arm started 4 hours post shot.  dramatic swelling and moderate pain in armpit with at least one lymph node affected, started 24 hours post shot.  night sweats, 4 days post shot.
03/15/2021: Presented to the emergency department after an outpatient MRI showed a subdural hematoma and the patient has expressive and receptive aphasia. Patient admitted for a craniotomy with evacuation of chronic subdural hematoma. The patient remains admitted at this time.
Vaccine with an expiration date of 6/17/2023 was administered to a patient after the expiration date; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a patient who received HAV (Havrix) (expiry date 17-JUN-2023) for prophylaxis.   In JUN-2023, the patient received Havrix. In JUN-2023, an unknown time after receiving Havrix, the patient experienced expired vaccine used (Verbatim: Vaccine with an expiration date of 6/17/2023 was administered to a patient after the expiration date). The outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 20-JUN-2023 The reporter from healthcare professional office stated that a havrix vaccine with an expiration date of 17-Jun-2023 was administered to a patient after the expiration date.  The reporter did not consented to follow-up. The patient received expired vaccine, which led to expired vaccine used.
None. This occurred in an immunization clinic for flood emergency workers - Full records were not used. No adverse event occurred, out of licensed age range.
1 day after receiving the vaccine patient has generalized abdominal pain/cramping and n/v and fatigue
Reported about one inch of swelling in left shoulder where vaccine was administered, stated there was tenderness. Donor stated that did not have any treatment and symptoms resolved on their own.
Systemic: Allergic: Difficulty Swallowing, Throat Tightness-Mild, Additional Details: Pt said she had Difficulty Swallowing, Throat Tightness. Pt was given benadryl and pt state she started to feel better after 5min. After 20min after the benadryl pt state she felt fine and did not have anymore symptoms.
My son woke up not walking properly. He looks like he is limping or walking sideways. Like if he had one leg shorter then the other one. No pain and no lumps where the vaccine was administrated.
The pt experienced fatigue, joint and muscle pain, abdominal pain, poor appetite, muscle weakness, skin rashes, fever, headache, inability to concentrate, memory loss, sleeplessness, and nausea.
This spontaneous report was received from a physician referring to an unknown number of patients of unknown gender and age. Pertinent medical history or concurrent conditions were not reported. Since 30-MAY-2017 (also reported as since 10-APR-2017), the patients were vaccinated with improperly stored doses of PEDVAXHIB which had the lot # reported as N00236, expiration date 24-OCT-2019, lot # N000235, expiration date 26-OCT-2019, lot # N003536, expiration date 02-NOV-2019, for prophylaxis (dosage information and route were not informed). Information regarding concomitant medication was not provided. Additionally, it was reported that the lowest temperature was 32 degrees Fahrenheit and the highest was 54 degrees Fahrenheit for 49 hours. Data logger was not involved. No adverse effects were reported. There was no product quality complaint involved. This is one case from several cases from the same reporter. Follow-up information has been received from a physician on 16-OCT-2017 to an unknown number of patients of unknown gender and age. The patients' concomitant medications, pertinent medical history, drug reactions or allergies were not reported. Since 29-APR-2017 (also reported as since 10-APR-2017), the patients were vaccinated with improperly stored doses of PEDVAXHIB (lot # M046140, expiration date 27-SEP-2019, dosage information and route were not provided) for prophylaxis. Additionally, it was reported that the lowest temperature was 47 degrees Fahrenheit and the highest was 49 degrees Fahrenheit for 16 hours. Data logger was not involved. No adverse effects were reported. There was no product quality complaint involved. This is one case from several cases from the same reporter. Follow up information was received from the physician on 16-OCT-2017. The patient was 6 months old. On 17-MAY-2017, the patient received a dose of improperly stored PEDVAXHIB (lot # M046140). The patient's identifiers and the patient's guardian's identifiers were provided. Sender's Comments: US-009507513-1709USA007325.
Pt recvd Rubella vax 28NOV88 & devel rheumatoid arthritis & was rendered otherwise sick, sore, lame, & disabled; Pt sustained severe shock to nervous system & was injured both internally & externally;
Facial swelling; extreme exhaustion; headache; skipped period; This is a spontaneous report from a contactable consumer (patient). A 37-years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: EW0191), via an unspecified route on 16Jun2021 at 17:30 (at the age of 37-years) as dose 2, single in the left arm for covid-19 immunisation. The patient medical history was not reported. The patient concomitant medications included venlafaxine, vitamin D from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: EW0182), via an unspecified route on 26May2021 at 17:30 (at the age of 37-years) as dose 1, single in the left arm for covid-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient experienced facial swelling, extreme exhaustion, headache and skipped period on 16Jun2021 at 23:00. Patient did not receive treatment for events. The patient underwent lab tests and procedures which included nasal swab was positive on 28May2021. The outcome of the events was not resolved.  Follow-up attempts are completed. No further information is expected.